Craig-Hallum Maintains Buy on BioLife Solns, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Matt Hewitt maintains a 'Buy' rating on BioLife Solns (NASDAQ:BLFS), but has lowered the price target from $29 to $23.

August 10, 2023 | 7:43 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BioLife Solns' price target has been lowered from $29 to $23 by Craig-Hallum, though the 'Buy' rating is maintained.
The news directly pertains to BioLife Solns. The lowering of the price target might indicate a potential downside, but the maintained 'Buy' rating suggests that the analyst still sees value in the stock. This could lead to mixed market reactions, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100